We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

52 hedge funds and large institutions have $78.7M invested in Catalyst Pharmaceutical in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $1.54M | Put options by funds: $656K

39% more capital invested

Capital invested by funds: $56.4M → $78.7M (+$22.3M)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 47 → 52 (+5)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
12
Reduced
10
Closed
13
Calls
$1.54M
Puts
$656K
Net Calls
+$883K
Net Calls Change
+$816K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$11.7M
2
Morgan Stanley
Morgan Stanley
New York
+$3.23M
3
SFM
Sphera Funds Management
Israel
+$1.79M
4
TC
TFS Capital
Pennsylvania
+$599K
5
Renaissance Technologies
Renaissance Technologies
New York
+$514K

Top Sellers

1
O
OrbiMed
New York
-$4.79M
2
PA
Perceptive Advisors
New York
-$3.79M
3
BC
Broadfin Capital
New York
-$2.61M
4
SC
Sophrosyne Capital
New York
-$1.52M
5
GTC
Ghost Tree Capital
New York
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$22.3M +$11.7M +4,492,409 +202%
Federated Hermes
2
Federated Hermes
Pennsylvania
$10.1M -$357K -136,500 -4%
Franklin Resources
3
Franklin Resources
California
$8.34M -$204K -77,900 -3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$6.23M +$227K +86,807 +5%
VAM
5
Visium Asset Management
New York
$4.98M – – –
BC
6
Broadfin Capital
New York
$4.65M -$2.61M -1,000,000 -42%
Morgan Stanley
7
Morgan Stanley
New York
$4.1M +$3.23M +1,236,179 New
OM
8
Opaleye Management
Massachusetts
$3.24M -$1.05M -403,584 -29%
CCA
9
Catalyst Capital Advisors
New York
$3.17M +$327K +125,000 +15%
SFM
10
Sphera Funds Management
Israel
$2.28M +$1.79M +685,500 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$937K -$39K -14,926 -5%
AQR Capital Management
12
AQR Capital Management
Connecticut
$798K – – –
Deutsche Bank
13
Deutsche Bank
Germany
$789K +$491K +187,800 +376%
TC
14
TFS Capital
Pennsylvania
$760K +$599K +229,040 New
Renaissance Technologies
15
Renaissance Technologies
New York
$652K +$514K +196,500 New
BFA
16
BlackRock Fund Advisors
California
$583K +$43.9K +16,804 +11%
WMSA
17
Weiss Multi-Strategy Advisers
New York
$498K -$157K -60,000 -29%
TCM
18
Tanaka Capital Management
New York
$414K – – –
Northern Trust
19
Northern Trust
Illinois
$297K -$5.82K -2,228 -2%
Citadel Advisors
20
Citadel Advisors
Florida
$275K +$160K +61,341 +284%
Millennium Management
21
Millennium Management
New York
$275K +$216K +82,770 New
Bank of America
22
Bank of America
North Carolina
$260K +$7.84K +3,000 +4%
CI
23
Cowen Inc
New York
$255K +$278K +106,250 New
PP
24
Paloma Partners
Connecticut
$239K +$188K +71,994 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$222K -$149K -56,939 -46%
1
2 3

CPRX Hedge Fund Activity: Q3 2014 in Review

52 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2014, worth a combined $78.7M — up 39% from $56.4M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CPRX positions and 13 closed out — a net gain of 5 holders — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was OrbiMed, exiting entirely with an estimated $4.79M sold.

  • 52 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2014, up from 47 in Q2 2014.
  • Funds reported $78.7M of Catalyst Pharmaceutical stock for Q3 2014, up 39% quarter-over-quarter.
  • 18 funds opened new Catalyst Pharmaceutical positions in Q3 2014 and 13 closed out, a net change of +5 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2014 was Baker Bros. Advisors, an estimated $11.7M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2014 was OrbiMed, an estimated $4.79M sold.

Based on aggregated 13F filings for Q3 2014.